Suppr超能文献

左心室辅助装置用于终身支持。

Left Ventricular Assist Devices for Lifelong Support.

机构信息

Zena and Michael Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

J Am Coll Cardiol. 2017 Jun 13;69(23):2845-2861. doi: 10.1016/j.jacc.2017.04.031.

Abstract

Continuous-flow left ventricular assist devices (LVADs) have revolutionized advanced heart failure care. These compact, fully implantable heart pumps are capable of providing meaningful increases in survival, functional capacity, and quality of life. Implantation volumes continue to grow, but several challenges remain to be overcome before LVADs will be considered as the therapy of choice for all patients with advanced heart failure. They must be able to consistently extend survival for the long term (7 to 10 years), rather than the midterm (3 to 5 years) more typical of contemporary devices; they must incorporate design elements that reduce shear stress and avoid stasis to reduce the frequent adverse events of bleeding, stroke, and pump thrombosis; and they must become more cost-effective. The advancements in engineering, implantation technique, and medical management detailed in this review will highlight the progress made toward achieving lifelong LVAD support and the challenges that remain.

摘要

连续流动左心室辅助装置(LVAD)彻底改变了心力衰竭的治疗方式。这些紧凑、完全可植入的心脏泵能够显著提高生存率、功能能力和生活质量。植入量持续增长,但在 LVAD 被视为所有晚期心力衰竭患者的首选治疗方法之前,仍有几个挑战需要克服。它们必须能够长期(7 至 10 年)而不是中期(3 至 5 年)持续延长生存时间,这是当代设备更典型的情况;它们必须采用减少剪切力和避免停滞的设计元素,以减少出血、中风和泵血栓等频繁发生的不良事件;而且它们必须更具成本效益。本综述详细介绍了工程、植入技术和医疗管理方面的进展,突出了实现终身 LVAD 支持的进展以及仍然存在的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验